Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV

Springer Science and Business Media LLC - Tập 18 Số 1 - 2021
Charlotte-Paige Rolle1, Vu Cong Nguyen2, Federico Hinestrosa1, Edwin DeJesus1
1Orlando Immunology Center, 1707 North Mills Avenue, Orlando, FL, 32803, USA
2University of Central Florida College of Medicine, 6850 Lake Nona Blvd., Orlando, FL, 32827, USA.

Tóm tắt

AbstractBackgroundDolutegravir (DTG) monotherapy results in virologic failure and the development of DTG resistance. Here, we evaluated virologic outcomes of patients switched to DTG functional mono- or dual therapy with a non-cytosine nucleoside analog (NA).MethodsThis retrospective, single center study included treatment-experienced patients switched to regimens containing ≥ 2 antiretrovirals between 8/13/13–11/22/14 who were later found to be on DTG functional mono- or dual therapy with a non-cytosine NA based on historical genotypes. Eligible patients were either suppressed or viremic at baseline and had ≥ 2 HIV-1 RNA measurements at least 4 weeks apart following switch. Demographics, laboratory values and clinical parameters were extracted from the charts of all eligible patients during study treatment until 12/31/2018 and were summarized using descriptive statistics. The primary endpoint was the proportion of patients with HIV-1 RNA < 50 copies/mL following switch.ResultsOf 70 patients switched to DTG functional mono- or dual therapy, 39 were eligible; 19 (49%) were on DTG functional monotherapy and 20 (51%) were on DTG functional dual therapy with a non-cytosine NA. Historical genotypes indicated that all had an M184V/I, and 23 (59%) had an M184V/I and ≥ 1 additional NA mutation. The median duration of follow-up on study treatment was 50 weeks (range 12–244). Following switch, 32/39 (82%) patients achieved or maintained an HIV-1 RNA < 50 copies/mL and 7 (18%) had persistent HIV-1 RNA ≥ 50 copies/mL. Five viremic patients were found to be on functional dual therapy with DTG plus a non-cytosine NA and 2 were on DTG functional monotherapy. Five of these patients had post-switch genotypes ordered as a part of routine clinical care and there was no evidence of treatment-emergent resistance. Five were switched to a different DTG-containing regimen and achieved HIV-1 RNA < 50 copies/mL, 1 was switched to a non-DTG containing regimen and achieved HIV-1 RNA < 50 copies/mL and 1 was lost-to-follow up at week 36.ConclusionsIn this real-world cohort, the majority of whom had virus with the M184V/I and ≥ 1 additional NA mutation, switching to DTG functional mono-or dual therapy with a non-cytosine NA resulted in persistent HIV-1 RNA ≥ 50 copies/mL in 18%. None with post-switch genotypes developed treatment-emergent resistance.

Từ khóa


Tài liệu tham khảo

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment–naive adults with HIV-1 infection—3-year results from the gemini studies. Poster P018. HIV Drug Therapy Glasgow 2020; October 5–8, 2020, Virtual.

van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (Tango study). Oral O441. HIV Drug Therapy Glasgow 2020; October 5–8, 2020, Virtual.

Llibre JM, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839–49.

van Wyk J, et al. Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;85(3):325–30.

Wijting I, et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV. 2017;4(12):e547–54.

Blanco JL, et al. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. J Antimicrob Chemother. 2018;73(7):1965–71.

Hocqueloux L, et al. Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for virologically suppressed people living with chronic human immunodeficiency virus infection: the randomized noninferiority MONotherapy of TiviCAY trial. Clin Infect Dis. 2019;69(9):1498–505.

Boffito M, et al. Perspectives on the barrier to resistance for dolutegravir + lamivudine, a two-drug antiretroviral therapy for HIV-1 infection. AIDS Res Hum Retrovir. 2020;36(1):13–8.

World Health Organization (WHO). Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Interim guidelines. 2018. https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51.

Vitoria M, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1551–61.

Kouamou V, et al. Pretreatment HIV drug resistance among adults initiating or re-initiating first-line antiretroviral therapy in Zimbabwe: fast-tracking the transition to dolutegravir-based first-line regimens? AIDS Res Hum Retrovir. 2021. https://doi.org/10.1089/aid.2020.0242.

World Health Organisation (WHO). HIV drug resistance report. Geneva: World Health Organization; 2019.

Jordan MR, et al. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Medicine (Baltimore). 2020;99(37):e21661.

TenoRes Study, G. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16(5):565–75.

Borghetti A, et al. Shall we dance? Extending TANGO’s results to clinical practice. Clin Infect Dis. 2020;71(7):e200–1.

Gagliardini R, et al. Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study. Open Forum Infect Dis. 2018;5(6):ofy113.

Rial-Crestelo D, et al. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: week 96 results of ART-PRO pilot study. J Antimicrob Chemother. 2021;76(3):738–42.

Wang R, Wright J, Ait-Khaled M, Tenorio AR, Nascimento MC, et al. Assessing the virologic impact of archived resistance in an HIV-1 switch study, Tango. Abstract 489. CROI 2020, March 8–11, Boston, MA.

Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–18.

Wensing AM, et al. 2017 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2017;24(4):132–3.

Aboud M, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19(3):253–64.

Santoro MM, Armenia D, Teyssou E, Santos JR, Charpentier C, et al. Impact of M184V on the virological efficacy of switch to 3TC/DTG in Real Life. Abstract 429. CROI 2021. Virtual, March 6–10, 2021.

Ndashimye E, Arts EJ. Dolutegravir response in antiretroviral therapy naive and experienced patients with M184V/I: impact in low-and middle-income settings. Int J Infect Dis. 2021;105:298–303.

Rosenblum M, et al. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE. 2009;4(9):e7196.

Giacomelli A, et al. No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference. Antivir Res. 2019;172:104635.

Benzie AA, et al. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS. 2007;21(11):1423–30.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 18 Số 1

Thông tin tác giả